Nordion Inc. NDN NDZ, a leading provider of products and
services for the prevention, diagnosis and treatment of disease,
announced that it has entered into an agreement to divest its Targeted
Therapies business to BTG plc BTG (“BTG”), an international
specialist healthcare company based in London, United Kingdom, for a
cash purchase price of US$200 million. Net of cash taxes and transaction
costs, Nordion expects to realize approximately US$185 million on
closing. The transaction is anticipated to be completed by the end of
June 2013.
Nordion manufactures and commercializes TheraSphere®, a targeted liver
cancer therapy, the sole product in its Targeted Therapies business.
Under the terms of the transaction agreements, BTG is expected
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in